Cantor Fitzgerald Downgrades Sunesis Pharmaceuticals Inc. (SNSS) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow rise as AI boost counters US-Iran tensions
- Oil retreats from one-month high as traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Google defeats US bid to force ad tech sale
Sunesis Pharmaceuticals Announces Regulatory Update
July 23, 2015 4:06 PM EDTCompany to Proceed Expeditiously With Marketing Authorization Application in Europe and Will Evaluate Regulatory and Clinical Strategies to Gain Marketing Approval in the U.S.
Sunesis to Host Conference Call Today at 5:00 PM Eastern Time
SOUTH SAN FRANCISCO, Calif., July 23, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced regulatory updates from its interactions with the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) regarding a potential path toward marketing authorization for vosaroxin as a treatment for acute myeloid... More
